Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.